open access

Vol 56, No 3 (2005)
Original papers
Published online: 2006-03-24
Submitted: 2013-02-15
Get Citation

Impact of the mass-reductive therapy with orlistat on 25-(OH)-D3 and PTH concentration in sera of obese, menopausal women

Michał Holecki, Barbara Zahorska-Markiewicz, Teresa Nieszporek, Katarzyna Mizia-Stec, Magdalena Olszanecka-Glinianowicz, Agnieszka Żak-Gołąb, Piotr Kocełak, Agata Fryźlewicz-Moska, Andrzej Więcek
Endokrynologia Polska 2005;56(3):240-245.

open access

Vol 56, No 3 (2005)
Original papers
Published online: 2006-03-24
Submitted: 2013-02-15

Abstract

Epidemiological studies suggest a protective influence of obesity against postmenopausal bone loss. Lower risk of osteoporotic fractures was described in obese patients. However there were only a few studies which examined the effect of weight reduction on bone metabolism and results of these studies are controversial.
The aim of the study was to evaluate the influence of weight reduction program using Orlistat on bone metabolism in perimenopausal women. Twenty obese women with simple obesity and without concomitant diseases (BMI 37.1 ± 3.0 kg/m², mean age 49.8 ± 4.6 yrs) were enrolled into this study. The control group consisted of 20 healthy women (mean age 53.5 ± 5.4 yrs, BMI 24.1 ± 2.2 kg/m²). All patients have participated in a 3-month weight reduction therapy that consisted of: a 1000-1200 kcal/day balanced diet (daily calcium consumption about 500 mg), Orlistat 3x120 mg a day and regular physical exercises. Before the weight reduction therapy and after 10% reduction of body weight, serum concentrations of PTH, 25-(OH)-D3, total calcium and phosphorus, total cholesterol were assessed. Dual energy x-ray absorptiometry (DEXA method) of lumbar spine and femoral neck, measuring BMD was performed once, after a 3-month weight reduction therapy using Lunar DPXL. All these measurements were performed only once in control subjects.
After a 3-month weight reduction program in patients treated with Orlistat the mean weight loss was 11.6 ± 5.1 kg which is 12.1 ± 4.78%. BMI decreased from 37.1 ± 3.0 kg/m2 at baseline to 32.6 ± 2.7 kg/m2 post-treatment. The body weight reduction resulted in significant decrease of body fat and total cholesterol concentration. In obese subjects serum concentration of 25-(OH)-D3 was significantly lower and serum concentration of PTH was significantly higher in comparison to healthy controls, both before and after weight reduction therapy.Serum concentration of PTH, 25-(OH)-D3, total calcium and phosphorus did not change significantly after therapy with Orlistat.
Conclusion: 3-month weight reduction program using Orlistat did not influence significantly bone metabolism.

Abstract

Epidemiological studies suggest a protective influence of obesity against postmenopausal bone loss. Lower risk of osteoporotic fractures was described in obese patients. However there were only a few studies which examined the effect of weight reduction on bone metabolism and results of these studies are controversial.
The aim of the study was to evaluate the influence of weight reduction program using Orlistat on bone metabolism in perimenopausal women. Twenty obese women with simple obesity and without concomitant diseases (BMI 37.1 ± 3.0 kg/m², mean age 49.8 ± 4.6 yrs) were enrolled into this study. The control group consisted of 20 healthy women (mean age 53.5 ± 5.4 yrs, BMI 24.1 ± 2.2 kg/m²). All patients have participated in a 3-month weight reduction therapy that consisted of: a 1000-1200 kcal/day balanced diet (daily calcium consumption about 500 mg), Orlistat 3x120 mg a day and regular physical exercises. Before the weight reduction therapy and after 10% reduction of body weight, serum concentrations of PTH, 25-(OH)-D3, total calcium and phosphorus, total cholesterol were assessed. Dual energy x-ray absorptiometry (DEXA method) of lumbar spine and femoral neck, measuring BMD was performed once, after a 3-month weight reduction therapy using Lunar DPXL. All these measurements were performed only once in control subjects.
After a 3-month weight reduction program in patients treated with Orlistat the mean weight loss was 11.6 ± 5.1 kg which is 12.1 ± 4.78%. BMI decreased from 37.1 ± 3.0 kg/m2 at baseline to 32.6 ± 2.7 kg/m2 post-treatment. The body weight reduction resulted in significant decrease of body fat and total cholesterol concentration. In obese subjects serum concentration of 25-(OH)-D3 was significantly lower and serum concentration of PTH was significantly higher in comparison to healthy controls, both before and after weight reduction therapy.Serum concentration of PTH, 25-(OH)-D3, total calcium and phosphorus did not change significantly after therapy with Orlistat.
Conclusion: 3-month weight reduction program using Orlistat did not influence significantly bone metabolism.
Get Citation

Keywords

otyłość; terapia odchudzająca; obrót kostny; Orlistat

About this article
Title

Impact of the mass-reductive therapy with orlistat on 25-(OH)-D3 and PTH concentration in sera of obese, menopausal women

Journal

Endokrynologia Polska

Issue

Vol 56, No 3 (2005)

Pages

240-245

Published online

2006-03-24

Bibliographic record

Endokrynologia Polska 2005;56(3):240-245.

Keywords

otyłość
terapia odchudzająca
obrót kostny
Orlistat

Authors

Michał Holecki
Barbara Zahorska-Markiewicz
Teresa Nieszporek
Katarzyna Mizia-Stec
Magdalena Olszanecka-Glinianowicz
Agnieszka Żak-Gołąb
Piotr Kocełak
Agata Fryźlewicz-Moska
Andrzej Więcek

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl